Family Medicine · Poplar Bluff, MO
NPI
1841247848
Since 2006
Specialty
Family Medicine
Code 207Q00000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
225 Physicians Park Ste 400
Poplar Bluff, MO, 63901
Phone (573) 727-5500
Groups this clinician bills Medicare through
Medicare paid, 2024
$60K
932 services
Medicare patients, 2024
314
Average age 77
Drug cost, 2024
$4.0M
62,681 prescriptions
Company payments, 2025
$52.65
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher R Montgomery was code 99232 (hospital e&m - subsequent), 585 times for 221 patients. In total Christopher R Montgomery billed 932 services in 20 codes, and Medicare paid $60K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-03-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 585 | 221 | $60.73 | $36K |
| 99239 Hospital Discharge Management | Facility | 107 | 91 | $86.30 | $9,234 |
| 99222 Hospital E&M - Initial | Facility | 85 | 74 | $98.46 | $8,369 |
| 99231 Hospital E&M - Subsequent | Facility | 45 | 30 | $37.51 | $1,688 |
| 99238 Hospital Discharge Management | Facility | 34 | 31 | $61.49 | $2,091 |
| 77080 Standard X-ray | Office | 26 | 26 | $25.91 | $674 |
| 99233 Hospital E&M - Subsequent | Facility | 16 | 11 | $91.61 | $1,466 |
By year: 2022 $66K for 4,887 services; 2023 $44K for 2,375 services; 2024 $60K for 932 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80053 Clinical Chemistry | 438 | 330 | $10.35 | $4,533 |
| 85025 Blood Count | 364 | 284 | $7.61 | $2,770 |
| 83036 Blood Count | 197 | 152 | $9.52 | $1,875 |
| 82550 Clinical Chemistry | 144 | 138 | $6.38 | $919 |
| 80061 Clinical Chemistry | 126 | 123 | $13.12 | $1,653 |
| 84443 Clinical Chemistry | 110 | 85 | $16.46 | $1,811 |
| 84436 Clinical Chemistry | 88 | 66 | $6.73 | $592 |
| 84480 Clinical Chemistry | 73 | 56 | $13.90 | $1,015 |
| 82306 Clinical Chemistry | 65 | 52 | $29.01 | $1,886 |
| 81001 Clinical Chemistry | 65 | 54 | $3.07 | $199 |
Medicare prescription drug claims, 2024
In 2024, the drug Christopher R Montgomery prescribed most often to Medicare patients was Atorvastatin Calcium, with 2,560 prescriptions and refills. In total Christopher R Montgomery wrote 62,681 Medicare prescriptions that cost $4.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 2,560 | 3,680 | 360 | $26K |
| Pantoprazole Sodium Generic | 2,222 | 2,918 | 313 | $26K |
| Furosemide Generic | 2,044 | 2,477 | 260 | $11K |
| Amlodipine Besylate Generic | 1,891 | 2,941 | 298 | $12K |
| Levothyroxine Sodium Generic | 1,878 | 2,255 | 214 | $17K |
| Gabapentin Generic | 1,790 | 2,026 | 214 | $24K |
| Potassium Chloride Generic | 1,618 | 1,908 | 198 | $41K |
| Losartan Potassium Generic | 1,444 | 2,239 | 224 | $12K |
| Eliquis Apixaban | 1,330 | 1,460 | 136 | $558K |
| Tamsulosin Hcl Generic | 1,282 | 1,588 | 156 | $16K |
| Omeprazole Generic | 1,202 | 1,681 | 181 | $12K |
| Metoprolol Tartrate Generic | 1,119 | 1,405 | 137 | $7,445 |
| Rosuvastatin Calcium Generic | 1,092 | 1,609 | 152 | $14K |
| Lisinopril Generic | 1,076 | 1,478 | 150 | $7,785 |
| Carvedilol Generic | 999 | 1,320 | 132 | $6,693 |
Brand drugs: 7,468 claims; generic drugs: 54,373 claims; opioid claims: 1,168.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher R Montgomery $52.65 ($52.65 in general payments such as food, travel and fees) from 2 companies. The largest payer was Lundbeck LLC with $38.54.
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 1 | $38.54 |
| Amgen Inc. AMGN | 1 | $14.11 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.